Exscientia (NASDAQ:EXAI) Stock Price Up 6.2%

Exscientia plc (NASDAQ:EXAI – Get Rating)’s stock price rose 6.2% on Friday . The company traded as high as $6.53 and last traded at $6.48. Approximately 44,510 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 319,182 shares. The stock had previously closed at $6.10.

Wall Street Analysts Forecast Growth

Separately, Barclays decreased their target price on Exscientia from $40.00 to $12.00 and set an “overweight” rating for the company in a research report on Wednesday, November 16th.

Exscientia Trading Up 11.0 %

The stock has a 50 day simple moving average of $6.75 and a 200-day simple moving average of $7.14. The firm has a market capitalization of $818.40 million, a P/E ratio of -3.40 and a beta of 0.47. The company has a current ratio of 7.55, a quick ratio of 7.55 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Exscientia

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE grew its stake in shares of Exscientia by 65.5% during the 4th quarter. Bank of America Corp DE now owns 5,092 shares of the company’s stock valued at $27,000 after acquiring an additional 2,015 shares during the period. Citigroup Inc. grew its stake in shares of Exscientia by 127.2% during the 4th quarter. Citigroup Inc. now owns 11,910 shares of the company’s stock valued at $63,000 after acquiring an additional 6,669 shares during the period. UBS Group AG grew its stake in shares of Exscientia by 2,269.3% during the 4th quarter. UBS Group AG now owns 7,108 shares of the company’s stock valued at $38,000 after acquiring an additional 6,808 shares during the period. Raymond James & Associates bought a new position in shares of Exscientia during the 1st quarter valued at approximately $182,000. Finally, Renaissance Technologies LLC bought a new position in shares of Exscientia during the 2nd quarter valued at approximately $154,000. 22.36% of the stock is currently owned by institutional investors.

Exscientia Company Profile

(Get Rating)

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.